Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo ® (cemiplimab-rwlc)

Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO

Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss

Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 10, 2024, the US Department of Justice (“DOJ”) announced that it had filed a complaint against Regeneron under the False Claims Act alleging that the.

The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Regeneron (REGN) Could Beat Earnings Estimates Again

Regeneron Pharmaceuticals said on Monday the U.S. Justice Department's complaint against the company misreporting the average sales price for its macular degeneration drug Eylea is "meritless" and it plans to defend this case in court.

Regeneron to defend US Justice Department's complaint on drug-pricing manipulation

LOS ANGELES, CA / ACCESSWIRE / April 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.

Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea

Regeneron stock toppled Thursday after the DOJ filed a lawsuit saying the drugmaker fraudulently inflated the prices of its drug, Eylea.

Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?

Shares in biotech giant Regeneron Pharmaceuticals (REGN) go under the microscope Thursday after the U.S. Department of Justice (DOJ) accused the company of manipulating Medicare's drug pricing reporting by inflating the average sales price of its best-selling eye disease drug Eylea.

Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) faced a blow in pre-market trading after being hit with fraud allegations from the US Justice Department. Regeneron allegedly inflated the sales price of its macular degeneration drug Eylea to boost revenues from Medicare, according to the department.

Regeneron Pharma falls after US government alleges fraud

The U.S. Justice Department said on Wednesday it had filed a false claims act complaint against Regeneron Pharmaceuticals , claiming the company filed false average sales price reports.

US Justice department files complaint against Regeneron, alleges fraudulent drug pricing

Exelixis

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?

EXEL or REGN: Which Is the Better Value Stock Right Now?

Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)

Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron failed to earn approval for a cancer medicine. The company could launch another one later this year.

Should You Sell This Stock Following a Regulatory Roadblock?

TARRYTOWN, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 2, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024

Eli Lilly

Shares of Eli Lilly and Regeneron have risen sharply thanks to their strong results and product approvals. Though both drugmakers could undertake stock splits, their prospects don't depend on their doing so.

Stock-Split Watch: Are These 2 Top Growth Stocks Next?

Regeneron Pharmaceuticals, Inc.'s Eylea HD reinforces its market dominance in treating wet AMD, competing effectively against biosimilars and Roche's Vabysmo. Libtayo's revenue growth is impressive, with expectations to become a blockbuster, enhancing Regeneron's oncology presence. Regeneron benefits financially from Dupixent sales and a strong balance sheet, indicating robust financial health and investment in pipeline development.

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Regeneron's (REGN) efforts to expand its oncology portfolio get a hit as the FDA refuses to approve the lymphoma drug odronextamab.

Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA

BioNTech SE

Vertex Pharmaceuticals

As we step into March 2024, the spotlight is turning towards the biotech sector, with investors searching for biotech stocks to buy. Biotech stocks are ready to soar after a period of under-performance relative to the broader market.

3 Biotech Stocks to Buy for the Next Bull Run: March 2024

TARRYTOWN, N.Y., March 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued Complete Response Letters (CRLs) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R) follicular lymphoma (FL) and in R/R diffuse large B-cell lymphoma (DLBCL), each after two or more lines of systemic therapy. The only approvability issue is related to the enrollment status of the confirmatory trials. The CRLs – one for R/R FL and one for R/R DLBCL – did not identify any approvability issues with the odronextamab clinical efficacy or safety, trial design, labeling or manufacturing.

Regeneron Provides Update on Biologics License Application for Odronextamab

Roche Holding AG

Prescription weight loss drugs, like GLP-1 agonists and orlistat, offer effectiveness for some individuals and have proven effects the market has taken notice of. These drugs focus on curbing appetite, which investors in weight loss drug stocks have noticed.

Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs

Novartis

A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders including permanent blindness.

US appeals court revives Regeneron's antitrust lawsuit against Novartis

Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript)

PDS Biotechnology Corporation

Pfizer

Biotech stocks are not for investors with a low-risk tolerance. This sector has stocks that are either considered blue-chip names or pre-revenue lotto tickets.

The 3 Most Undervalued Biotech Stocks to Buy in March 2024

$250,000 top award goes to Achyuta Rajaram in the nation's oldest and most prestigious Science, Technology, Engineering and Math  (STEM) competition for high school seniors TARRYTOWN, N.Y. and WASHINGTON, March 12, 2024 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.  (NASDAQ: REGN) and Society for Science  (the Society) announced that Achyuta Rajaram, 17, of Exeter, NH, won the top award in the Regeneron Science Talent Search (STS) 2024, America's oldest and most prestigious science and math competition for high school seniors.

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

News for Regeneron Pharmaceuticals Stock (REGN)